Tuning the Immune System to Fight Cancer

Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence

 

Our Approach

Proprietary Technologies

Immunetune has developed unique proprietary technologies enabling next-generation best-in-class DNA vaccines against cancer and infectious diseases.

read more

Pipeline

Lead program NeoVAC is a personalized neoantigen DNA vaccine harboring more than 20 neoantigens to elicit powerful tumor-specific immune responses.

read more

Unique Differentiators

DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide and RNA vaccines and cell therapies.

read more

Company Highlights

Finalizing preclinical package to initiate clinical studies in 2022

Preclinical Proof of Concept in cancer models including combination with checkpoint inhibitors

Seeking funding by life science investors and partnerships in oncology & infectious diseases

About Us

Company Background

Immunetune is based in Leiden, the Netherlands, and is committed to develop best-in-class vaccines and bring them to patients with a sense of purpose and urgency.

read more

Our Team

Our highly motivated team combines the right scientific and corporate experience. Immunetune’s scientists have vast expertise in immunology, molecular biology, and a long-standing collaboration with Leiden University Medical Center, among others.

read more

News & Events

BIO-Europe, 25-28 October 2021

BIO-Europe, 25-28 October 2021

BIO-Europe, 25-28 October 2021 Sijme Zeilemaker, CEO of Immunetune, will be attending BIO-Europe, taking place October 25-28, 2021, in digital format. Feel free to reach out to us to set up a meeting and explore collaboration and investment opportunities. E-mail:...

read more
Other News

Contact us

    I hereby confirm that I have fully read and accept Immunetune's privacy statement.

    Click here to read our privacy statement.